Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy.
Daan J ReesinkMelline G M SchilhamErik J R J van der HoevenIvo G SchootsHarm H E van MelickRoderick C N van den BerghPublished in: World journal of urology (2020)
Upfront bpMRI as a risk stratification tool outperforms risk-calculator in detecting significant disease. Applying the risk-calculator first to decide on performing an MRI, avoids 1 out of 2 MRIs, but up to 1 out of 5 significant cancers are missed.